BioXcel Therapeutics (BTAI) Profit After Tax (2022 - 2025)
Historic Profit After Tax for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$30.9 million.
- BioXcel Therapeutics' Profit After Tax fell 12645.42% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$68.2 million, marking a year-over-year increase of 392.28%. This contributed to the annual value of -$59.6 million for FY2024, which is 6671.43% up from last year.
- Per BioXcel Therapeutics' latest filing, its Profit After Tax stood at -$30.9 million for Q3 2025, which was down 12645.42% from -$19.2 million recorded in Q2 2025.
- BioXcel Therapeutics' 5-year Profit After Tax high stood at -$7.3 million for Q1 2025, and its period low was -$54.8 million during Q4 2022.
- Over the past 4 years, BioXcel Therapeutics' median Profit After Tax value was -$30.9 million (recorded in 2025), while the average stood at -$30.8 million.
- Per our database at Business Quant, BioXcel Therapeutics' Profit After Tax soared by 8449.22% in 2024 and then tumbled by 13119.65% in 2025.
- Over the past 4 years, BioXcel Therapeutics' Profit After Tax (Quarter) stood at -$54.8 million in 2022, then surged by 59.39% to -$22.3 million in 2023, then soared by 51.21% to -$10.9 million in 2024, then tumbled by 184.66% to -$30.9 million in 2025.
- Its last three reported values are -$30.9 million in Q3 2025, -$19.2 million for Q2 2025, and -$7.3 million during Q1 2025.